A Preliminary Policy Proposal ‘Salvage of histiocytic neoplasms causing life-threatening disease with mitogen-activated protein kinase (MAPK) inhibitors’

A Preliminary Policy Proposal  ‘Salvage of histiocytic neoplasms causing life-threatening disease with mitogen-activated protein kinase (MAPK) inhibitors’ has been submitted to NHS England on 2nd November. This advises the NHS to develop a commissioning policy for access to Vemurafenib, Dabrafenib, Cobimetinib and Trametinib.The next step is a review by the Specialised Commissioning Panel to determine whether the policy will be adopted onto the work flow.  From this point it will take at least 12 months for NHSE to develop a commissioning policy after wide consultation with all of the relevant stake holders, including a number of patients, families and Histio UK.